J&J inks an $835M RNA deal to develop autoimmune drugs with Isis

January 5, 2015 1:51 PM

12 0

You can now count Johnson & Johnson ($JNJ) among the roster of big companies to ally itself with Isis Pharmaceuticals' ($ISIS) R&D group. J&J has stepped up with an $835 million pact to develop new drugs for autoimmune diseases of the gastrointestinal tract with the RNA specialists at Isis.

Just a few months after AstraZeneca ($AZN) expanded its development work with Isis, J&J is paying $35 million upfront and offering up to $800 million in milestones for the deal. Isis also stands to earn royalties from any marketed drugs that comes from its antisense technology platform.

Also read: T-Mobile taking over Dutch arm of Tele2 mobile provider

Read more

To category page